BRIDGE for Young-Onset Alzheimer’s Disease Act of 2025
- Sponsor
- Rep. Kim, Young [R-CA-40]
- Committees
- Ways and Means Committee (primary)
- Last action
- Dec 17, 2025
Bottom line
The bill aims to provide faster access to critical disability and healthcare benefits for individuals diagnosed with young-onset Alzheimer's disease.
What it actually does
This bill eliminates the standard waiting periods for Social Security Disability Insurance (SSDI) benefits and Medicare coverage for individuals diagnosed with young-onset Alzheimer's disease. Currently, individuals typically face a five-month waiting period for SSDI and a 24-month waiting period for Medicare after becoming eligible. The bill aligns young-onset Alzheimer's with conditions like Amyotrophic Lateral Sclerosis (ALS), which are already exempt from these waiting periods.
Proponents argue
Supporters argue that individuals diagnosed with young-onset Alzheimer's face a rapidly progressive and devastating illness that severely impacts their ability to work and live independently, often at a younger age than typical Alzheimer's. Eliminating waiting periods would provide immediate financial relief and access to necessary medical care, reducing the immense burden on affected individuals and their families during a critical time. They contend it offers equitable treatment, similar to other severe conditions like ALS.
Opponents contend
Critics, while acknowledging the severity of young-onset Alzheimer's, might raise concerns about the potential long-term fiscal impact on the Social Security and Medicare trust funds. They could argue that expanding exemptions for waiting periods, even for a deserving cause, sets a precedent that could lead to similar requests for other conditions, potentially straining federal budgets without corresponding revenue increases. Some might also question the administrative burden of defining and verifying 'young-onset Alzheimer's' for these purposes.
The bill is very short and clear, making it easy to read and understand its core provisions quickly.
Section 2
Elimination of Disability Insurance Waiting Period
This section amends the Social Security Act to remove the five-month waiting period for Social Security Disability Insurance (SSDI) benefits for individuals diagnosed with young-onset Alzheimer's disease. This means that once an individual with young-onset Alzheimer's is determined to be disabled, their SSDI benefits would begin immediately, rather than after a five-month delay. The Commissioner of Social Security is tasked with defining 'young-onset Alzheimer's' for this purpose through official program manuals.
Supporters argue
Proponents argue that the rapid progression and debilitating nature of young-onset Alzheimer's necessitate immediate financial support, as affected individuals often lose their ability to work and earn income quickly. Eliminating the waiting period provides crucial income when it is most needed, preventing financial hardship and allowing families to focus on care.
Critics contend
Opponents, while sympathetic to the condition, might express concern about the precedent this sets for other severe diseases and the cumulative impact on the solvency of the Social Security Disability Insurance trust fund. They may argue for a broader review of disability benefit structures rather than piecemeal exemptions.
Tradeoffs
The provision balances the humanitarian need for immediate support for a devastating illness against concerns about the long-term financial stability of the Social Security system and the potential for expanding similar exemptions.
Section 3
Waiver of 24-Month Medicare Waiting Period
This section waives the standard 24-month waiting period for Medicare coverage for individuals with young-onset Alzheimer's disease. Currently, most individuals who qualify for SSDI must wait two years after their disability entitlement date before their Medicare coverage begins. This amendment would allow individuals with young-onset Alzheimer's to access Medicare benefits immediately upon qualifying for SSDI, ensuring timely access to essential medical care. The definition of 'young-onset Alzheimer's' will be consistent with that established by the Commissioner.
The bill delegates the definition of 'young-onset Alzheimer's' to the Commissioner of Social Security through the Program Operations Manual System (POMS) or a successor document.
Section 2(a)(1) and Section 3(a)
Why it matters:Delegating definitions to agency manuals is a common legislative practice, allowing for flexibility and technical detail that might be too cumbersome for statutory language. However, it can also make the precise scope and eligibility criteria less transparent to the public.
Case for: Supporters argue that allowing the Commissioner to define 'young-onset Alzheimer's' provides necessary flexibility to adapt to evolving medical understanding and diagnostic criteria without requiring new legislation. It ensures that the definition can be updated efficiently by medical experts within the agency.
Case against: Critics might contend that delegating such a crucial definition to an internal manual reduces transparency and public accountability. They could argue that the specific criteria for eligibility should be clearly outlined in the statute itself, allowing for greater public scrutiny and congressional oversight.
Estimated impact: The precise number of individuals who will qualify for these benefits depends entirely on how 'young-onset Alzheimer's' is defined by the Commissioner, directly impacting the fiscal cost and the scope of the bill's benefits.